The present invention provides IFN.alpha.2 mutants and active fragments, analogs, derivatives, and variants thereof that have improved specific agonist or antagonist activity as compared to wild-type IFN.alpha.2. The present invention further provides pharmaceutical compositions comprising IFN.alpha.2 mutants useful for treating or preventing cancer, autoimmune diseases, infectious diseases or disorders associated with increased expression of IFN.alpha.2.